# A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

> **NCT03204032** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Extrapancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Tegafur
- **DRUG:** Temozolomide
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT03204032
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2017-10
- **Final completion:** 2018-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204032, "A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03204032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*